Level B· Emerging clinical evidence with positive signalsRandomized Controlled TrialPubMed

Comparing the potential efficacy of stromal vascular fraction and adipose mesenchymal stem cell-derived exosomes in a rat model of chromium-induced thyroid dysfunction.

Hosny SA., ShamsEldeen AM., Mohamed EEE., Alkaffas M., Hassan RM., Mostafa SMS.

Randomized Controlled Trial with a reported sample of 10 on Chronic Inflammation, published in Tissue Cell (2026) — summary generated from the PubMed abstract.

Open my reading list
Level B· Emerging clinical evidence with positive signalsEvidence level of this study

Several human studies show positive signals, while research methods and sample sizes continue to develop.

  • Level A · Stronger Clinical Evidence
  • Level B · Emerging clinical evidence with positive signals
  • Level C · Early human research exploring benefits
  • Level D · Scientific groundwork from lab and animal studies
  • Emerging · Emerging topic under active research
Read the A–D evidence level guide

This page is generated from the PubMed record. The Thai description is an automated summary of bibliographic fields and the abstract, not a full translation, and is not medical advice.

Study type
Randomized Controlled Trial
Journal
Tissue Cell (2026)
Country
Scotland
Reported sample size
10
Source database
PubMed
PMID
41990699
DOI
10.1016/j.tice.2026.103531

Abstract (original English)

Background Occupational exposure to toxic heavy metals may render industrial workers susceptible to thyroid-related problems. Chromium (Cr) in its hexavalent form is highly toxic and a known carcinogen. This research is the first experimental study to investigate the possible protective role of adipose mesenchymal stem cell (MSC)-derived exosomes (ADMSCs-E) versus stromal vascular fraction (SVF) exosomes in a rat model of Cr-induced thyrotoxicity, using behavioral, histological, immunohistochemical, and biochemical studies, with correlation assessed using morphometric and statistical methods. Methods Forty-two male rats were randomly assigned to a donor group (n = 10) for preparation of ADMSCs-E and SVF and four experimental groups (n = 8 each): control, Chromium-treated (60 μg/kg I.P), Exosomes-treated, and SVF-treated groups. Behavioral changes were assessed through the open field and elevated plus maze (EPM) tests. Blood samples were collected to measure T3, T4, TSH, tumor necrosis factor-alpha (TNF-α), and malondialdehyde (MDA) in serum. Thyroid tissues were then subjected to histological, immunohistochemical, ultrastructural, and morphometric analyses. Additionally, Pax3 mRNA expression was evaluated using qRT-PCR. Results Following exposure to potassium dichromate, the thyroid histological and ultrastructural architecture was significantly disrupted, leading to altered th

What this study does not prove

  • • This study does not prove SVF is an approved treatment or a replacement for standard care.

Evidence level

Several human studies show positive signals, while research methods and sample sizes continue to develop.

How we grade evidence
AnimalsMesenchymal Stem CellsExosomesMaleRatsChromiumDisease Models, AnimalAdipose TissueThyroid GlandThyroid Diseases

Browse all related research

Filter the research library by this study's title keywords, author, or publication year.

Related research